Mr. Liu fully acknowledged Mabwell’s efforts in developing antibody drugs for Covid-19 while at the same time controlling the spread of the virus. He encouraged the company to make full use of its own strengths to step up R&D efforts and assured the company that the Commission would facilitate resources to support companies in their research and development of drugs. He expressed his hope for the company to utilize the services provided by the Commission to develop new drugs with its own IP, to help in the fight against Covid-19, and to be a representative company in pharmaceutical technology development in Shanghai.
Dr. Liu expressed his gratitude for the support from Mr. Liu and the Commission and spoke of his confidence in developing valuable new drugs in Shanghai where the environment is favorable for pharmaceutical innovation.